|
gptkbp:instanceOf
|
gptkb:drug
benzodiazepine
|
|
gptkbp:ATCCode
|
N03AE01
|
|
gptkbp:brand
|
gptkb:Klonopin
gptkb:Rivotril
|
|
gptkbp:broadcastOn
|
Schedule IV (US)
|
|
gptkbp:CASNumber
|
1622-61-3
|
|
gptkbp:contraindication
|
acute narrow-angle glaucoma
severe liver disease
|
|
gptkbp:developedBy
|
gptkb:Hoffmann-La_Roche
|
|
gptkbp:discoveredBy
|
gptkb:Leo_Sternbach
|
|
gptkbp:eliminationHalfLife
|
18-50 hours
|
|
gptkbp:excretion
|
gptkb:kidney
|
|
gptkbp:hasMolecularFormula
|
C15H10ClN3O3
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
clonazepam
|
|
gptkbp:introducedIn
|
1975
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
GABA-A receptor positive allosteric modulator
|
|
gptkbp:meltingPoint
|
239–240 °C
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:proteinBinding
|
85%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL656
gptkb:DB01068
2699
2802
|
|
gptkbp:riskFactor
|
dependence
withdrawal symptoms
|
|
gptkbp:routeOfAdministration
|
oral
sublingual
|
|
gptkbp:sideEffect
|
dizziness
fatigue
drowsiness
impaired coordination
|
|
gptkbp:UNII
|
5PE9FDE8GB
|
|
gptkbp:usedFor
|
gptkb:panic_disorder
anxiety disorder
seizure disorder
|
|
gptkbp:bfsParent
|
gptkb:4-aminobutanoic_acid
gptkb:benzodiazepines
gptkb:benzodiazepine
|
|
gptkbp:bfsLayer
|
6
|